Core Viewpoint - Despite the closure of the Strait of Hormuz and escalating tensions in the Middle East, oil prices and the U.S. stock market have not experienced expected volatility, with current oil prices around $100 per barrel, significantly lower than historical crisis levels [3][4]. Oil Price Dynamics - The primary reasons for the restrained oil price increase include: 1. Low starting prices and ample inventory, with global oil stocks at a five-year high before the conflict, keeping prices manageable despite a nearly 40% surge in nine trading days [7]. 2. Market expectations of a quick resolution to the conflict, as indicated by futures market data showing that traders anticipate supply disruptions to last only a few weeks [7]. 3. Macro interventions, such as the release of 400 million barrels from reserves by the IEA and its member countries, which help stabilize oil prices despite a daily loss of 15 million barrels in shipping capacity [7]. Historical Context of Oil Crises - Historical oil crises have seen higher absolute prices, and current major economies have significantly reduced their dependence on oil for heating and power generation [11]. - Estimates suggest that oil futures may need to rise by an additional $40 to $50 to trigger an economic recession comparable to past crises, indicating a macroeconomic buffer that allows conflict parties to maintain their positions [12]. Impact on Global Economies - The price increase is causing more severe disruptions in developing economies, particularly in Asia, which face compounded risks from soaring oil prices and fuel shortages [14]. U.S. Stock Market Behavior - The U.S. stock market has shown resilience, largely due to the country's status as the largest oil producer, which insulates it from direct impacts of the energy crisis [15]. - An unusual market phenomenon has emerged where defensive sectors, typically seen as safe havens during geopolitical conflicts, have underperformed, with healthcare and consumer staples ETFs declining by approximately 5% and 6%, respectively [17]. Sector Rotation Insights - The rotation within the stock market is influenced by geographic exposure, with companies generating a higher percentage of revenue from North America showing better resilience against geopolitical shocks [22]. - Investors are shifting focus towards companies with strong growth potential rather than merely low valuations, favoring firms in the pharmaceutical sector that demonstrate solid earnings growth [22]. Cautionary Notes - Analysts warn that the current stability in asset prices relies on the fragile assumption that all parties desire a swift end to the conflict, with potential disruptions from unforeseen events capable of drastically altering market conditions [23][24].

Group 1 - The innovative drug sector in A-shares has shown a strong comeback, with multiple stocks experiencing significant price increases, including Shuyou Shen (20% increase) and Ruizhi Pharmaceutical (20% increase), indicating a bullish market sentiment [1] - The Hong Kong market also saw a rise, with WuXi AppTec increasing by 19.88% and several innovative drug ETFs in Hong Kong showing year-to-date gains exceeding 40%, outperforming similar products [1][2] - Analysts suggest that the domestic market is entering a concentrated listing period for innovative drugs, supported by comprehensive policy backing and improvements in commercial medical insurance, which are expected to enhance the commercialization process beyond market expectations [1][5] Group 2 - There is a noticeable divergence in the performance of various medical ETFs, with some experiencing significant inflows while others face substantial outflows, indicating mixed investor sentiment [2][3] - The top-performing innovative drug ETFs, such as ICBC Hong Kong Innovative Drug ETF and Huatai-PineBridge Hong Kong Innovative Drug ETF, have seen net inflows of 2.43 billion and 2.31 billion respectively, while the E Fund CSI 300 Healthcare ETF has recorded the highest net outflow of 2.5 billion [3] - The medical sector is expected to show its best performance in three years by mid-2025, driven by policy optimization and AI industry empowerment, with a clear trend of performance and valuation recovery anticipated in the second half of the year [3] Group 3 - The innovative drug sector has rebounded significantly after a period of decline, with innovative drug ETFs showing substantial weekly gains, particularly in the lead-up to the ASCO annual meeting, which has heightened industry interest [4] - The upcoming ASCO meeting is expected to showcase numerous original research results from Chinese pharmaceutical companies, indicating a shift towards international innovation in drug development [4][5] - Recent approvals of six domestic innovative drugs in May across critical treatment areas such as diabetes and tumors have injected strong momentum into the pharmaceutical industry [5]